Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

CMS considers Medicare coverage options for tricuspid valve repair at Abbott’s request

CMS is now accepting public comments on this topic until Nov. 2. A final decision is expected by July 2025.

Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

TRILUMINATE update: TEER with Abbott’s TriClip device still safe, effective after 3 years

Treatment with TriClip has been consistently associated with minimal adverse events and significant improvements in quality of life. This latest update represents data from nearly 100 patients three years after implantation.  

Thumbnail

Baseline TR linked to lower quality of life after TAVR, M-TEER—are more interventions the answer?

Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted. 

first-in-man valve-in-valve caval valve implantation

Cardiologists perform world’s first valve-in-valve caval valve procedure in heart transplant patient

A care team in Germany has completed what may be the first structural heart procedure of its kind on a high-risk patient. It started as a straightforward heterotopic caval valve implantation, but then paravalvular leak resulted in a change of plans. 

Cardiovalve heart valve transfemoral TMVR TTVR

Cardiologists first in world to use new heart valve for TMVR, TTVR on same patient

Identical Cardiovalve systems were used to perform the procedures 18 months apart on a high-risk heart patient. 

healthcare value value-based care money dollar

Cardiology Funding Roundup: Cardurion, Kestra, TRiCares all secure key investments

Businesses in the cardiovascular health space have been busy in recent weeks, announcing one big financing round after another. 

Surgeons Operating On Patient

Mechanical valves linked to superior long-term survival after tricuspid valve replacement

Each valve type has its own benefits, researchers noted, but mechanical valves are associated with multiple long-term benefits compared to tissue/bioprosthetic valves. 

M&A mergers and acquisitions business deal

Edwards Lifesciences sells critical care business to BD for $4.2B—remains ‘laser focused’ on structural heart disease

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup